Commitment and Contingencies (Tables)

9 Months Ended

Sep. 30, 2025

Commitments and Contingencies Disclosure [Abstract]

The components of lease expense were as follows (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Total operating lease cost	$	978	$	1,119	$	3,042	$	3,358

Supplemental Cash Flow Information Related to Leases

Supplemental cash flow information related to leases was as follows (in thousands):


	Nine Months Ended September 30,
	2025		2024
Operating cash flows from operating leases	$	3,799	$	3,644

Schedule by Year for Future Maturities of Operating Lease Liabilities and Sublease Income to be Received

The following is a schedule by year for future maturities of the Company’s operating lease liabilities and sublease income to be received as of September 30, 2025 (in thousands):


	Operating Leases			Sublease Income
2025	$	1,323		$	370
2026		5,399			1,500
2027		5,584			81
2028		5,775			—
2029		5,974			—
Thereafter		8,789			—
Total lease payments		32,844			1,951
Less interest		(9,255	)		—
Total	$	23,589		$	1,951

Bolt Biotherapeutics, Inc. 10-Q